Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | MAX | P61244 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6888440 | 0.99 | KMT2A (0.49) | KMT2AALDH1A1PKMHGFACMAPT | |
| SCHEMBL10677499 | 0.84 | HPGD (0.51) | KMT2AALDH1A1MAPTKDM4EGAA | |
| SCHEMBL5078869 | 0.81 | ALDH1A1 (0.56) | KMT2AALDH1A1MAPTKDM4EGAA | |
| SCHEMBL10699436 | 0.78 | CA2 (0.46) | ALDH1A1MAPTKDM4E | |
| SCHEMBL11417908 | 0.78 | PRSS1 (0.47) | ALDH1A1KDM4EGAA | |
| SCHEMBL4256409 | 0.77 | RAB9A (0.64) | KMT2AALDH1A1PKMHGFACMAPT | |
| SCHEMBL30258384 | 0.77 | RAB9A (0.64) | KMT2AALDH1A1PKMHGFACMAPT | |
| SCHEMBL237695 | 0.77 | KMT2A (0.64) | KMT2AALDH1A1PKMHGFACMAPT | |
| Hydrochloric Acid SCHEMBL377076 | 0.76 | KMT2A (0.63) | KMT2AALDH1A1PKMHGFACMAPT | |
| Guanidine SCHEMBL3748808 | 0.76 | KMT2A (0.67) | KMT2AALDH1A1PKMHGFACMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5955100-A | TREATMENT OF MALIGNANT TUMORS, INFLAMMATORY DISEASES, OR AUTOIMMUNE DISEASES | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1999-09-21 | — | — | US | claimed |
| US-20200121703-A1 | CANCER TREATMENT | THE CLEVELAND CLINIC FOUNDATION | 2020-04-23 | — | — | US | disclosed |
| WO-2019005754-A1 | CANCER TREATMENT | THE CLEVELAND CLINIC FOUNDATION (US) | 2019-01-03 | — | — | WO | disclosed |
| US-20110300147-A9 | Inhibiting tumor cell invasion, metastasis and angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-08 | — | — | US | disclosed |
| US-20090175873-A1 | Inhibiting tumor cell invasion, metastasis and angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-07-09 | — | — | US | disclosed |
| EP-1731164-A1 | Methods for using the obese gene and its gene product to stimulate hematopoietic development | Indevus Pharmaceuticals, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-0892849-B1 | METHODS FOR USING THE OBESE GENE AND ITS GENE PRODUCT TO STIMULATE HEMATOPOIETIC DEVELOPMENT | INDEVUS PHARMACEUTICALS INC (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050158287-A1 | Methods for using the obese gene and its gene product to identify hematopoietic progenitor cells | INDEVUS PHARMACEUTICALS, INC. | 2005-07-21 | — | — | US | disclosed |
| US-6838079-B2 | Methods for using the obese product to stimulate hematopoietic development | INDEVUS PHARMACEUTICALS, INC. (US) | 2005-01-04 | — | — | US | disclosed |
| US-20030186345-A1 | Macromolecular enzyme substrates | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH, THE | 2003-10-02 | — | — | US | disclosed |
| US-6146658-A | ADMINISTERING A GLYCOSYL-SPACER-DRUG COMPOUND WHERE THE GLYCOSYL IS A SACCHARIDE WHICH CAN BE ENZYMATICALLY CLEAVED; DRUG IS ANTIINFLAMMATORY, IMMUNOSUPPRESSIVE OR ANTITUMOR AGENT WHICH HYDROXYL OR AMINO GROUP; SELF-ELIMINATING SPACER | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-11-14 | — | — | US | disclosed |
| EP-0467932-B1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR | CANCERFORSKNINGSFONDEN AF 1989 (DK) | 2000-10-18 | — | — | EP | disclosed |
| EP-1013285-A2 | Urokinase-type plasminogen activator receptor | Cancerforskningsfonden af 1989 (fonden til fremme af eksperimentel cancerforskning) (DK) | 2000-06-28 | — | — | EP | disclosed |
| US-5955100-A | TREATMENT OF MALIGNANT TUMORS, INFLAMMATORY DISEASES, OR AUTOIMMUNE DISEASES | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1999-09-21 | — | — | US | disclosed |
| US-5891664-A | Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR) | CANCERFORSKNINGSFONDET AF 1989 (DK) | 1999-04-06 | — | — | US | disclosed |
| WO-1995000847-A1 | IMMUNOASSAY | HAFSLUND NYCOMED A.S (NO) | 1995-01-05 | — | — | WO | disclosed |
| US-5274162-A | Antineoplastic drugs with bipolar toxification/detoxification functionalities | GLAZIER ARNOLD (US) | 1993-12-28 | — | — | US | disclosed |
| WO-1993009233-A2 | RECOMBINANT AMYLOID PRECURSOR PROTEIN INHIBITOR DOMAIN AND TREATMENT OF VARIOUS DISEASE STATES | THE SALK INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSOCIATES INC. (US) | 1993-05-13 | — | — | WO | disclosed |
| EP-0467932-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR | Cancerforskningsfonden af 1989 (fonden til fremme af eksperimentel cancerforskning) (DK) | 1992-01-29 | — | — | EP | disclosed |
| WO-1990012091-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR | CANCERFORSKNINGSFONDET AF 1989 (DK) | 1990-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175873-A1 | Inhibiting tumor cell invasion, metastasis and angiogenesis | MMP9, TIMP3, MMP3 | KMT2A 3581/4885ALDH1A1 743/4885PKM 3004/4885 |
| US-20110300147-A9 | Inhibiting tumor cell invasion, metastasis and angiogenesis | MMP9, TIMP3, MMP3 | KMT2A 3581/4885ALDH1A1 743/4885PKM 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.